BR112017004459A2 - composições e métodos para o tratamento de distúrbios de proliferação - Google Patents
composições e métodos para o tratamento de distúrbios de proliferaçãoInfo
- Publication number
- BR112017004459A2 BR112017004459A2 BR112017004459A BR112017004459A BR112017004459A2 BR 112017004459 A2 BR112017004459 A2 BR 112017004459A2 BR 112017004459 A BR112017004459 A BR 112017004459A BR 112017004459 A BR112017004459 A BR 112017004459A BR 112017004459 A2 BR112017004459 A2 BR 112017004459A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- phenyl
- pyridin
- compositions
- aminocyclobutyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000035755 proliferation Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- KPJDVVCDVBFRMU-AREMUKBSSA-N (6r)-6-(2-fluorophenyl)-n-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine Chemical compound COCCNCCC1=CC=CC(NC=2N=C3C4=CC=CC=C4[C@H](C=4C(=CC=CC=4)F)CC3=CN=2)=C1 KPJDVVCDVBFRMU-AREMUKBSSA-N 0.000 abstract 1
- INXFFKMIBDOGPL-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-(3-morpholin-4-ylphenyl)imidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=NC2=CC=C(C=3C=C(C=CC=3)N3CCOCC3)N=C2N1C1=CC=C(C2(N)CCC2)C=C1 INXFFKMIBDOGPL-UHFFFAOYSA-N 0.000 abstract 1
- HNFMVVHMKGFCMB-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=NC2=CC=C(C=3C=CC=CC=3)N=C2N1C1=CC=C(C2(N)CCC2)C=C1 HNFMVVHMKGFCMB-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- NZDSLYATTDIDPH-UHFFFAOYSA-N vevorisertib Chemical compound C1CC(N(C)C(C)=O)CCN1C1=CC=CC(C=2N=C3N(C=4C=CC(=CC=4)C4(N)CCC4)C(C=4C(=NC=CC=4)N)=NC3=CC=2)=C1 NZDSLYATTDIDPH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046502P | 2014-09-05 | 2014-09-05 | |
| US201462082236P | 2014-11-20 | 2014-11-20 | |
| PCT/US2015/048520 WO2016037044A1 (en) | 2014-09-05 | 2015-09-04 | Compositions and methods for treating proliferation disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017004459A2 true BR112017004459A2 (pt) | 2017-12-05 |
Family
ID=55436479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017004459A BR112017004459A2 (pt) | 2014-09-05 | 2015-09-04 | composições e métodos para o tratamento de distúrbios de proliferação |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9949981B2 (https=) |
| EP (1) | EP3189036B1 (https=) |
| JP (2) | JP6574245B2 (https=) |
| KR (1) | KR20170045748A (https=) |
| CN (2) | CN111494378A (https=) |
| AU (2) | AU2015311751B2 (https=) |
| BR (1) | BR112017004459A2 (https=) |
| CA (1) | CA2958770A1 (https=) |
| ES (1) | ES2955926T3 (https=) |
| IL (2) | IL250715B (https=) |
| MX (1) | MX382891B (https=) |
| RU (2) | RU2019142694A (https=) |
| SG (1) | SG11201701704XA (https=) |
| WO (1) | WO2016037044A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230156450A (ko) | 2012-10-15 | 2023-11-14 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| US11561226B2 (en) | 2016-03-14 | 2023-01-24 | Pierce Biotechnology Inc. | Detection and quantification of AKT-mTOR pathway proteins |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| US20190350929A1 (en) * | 2017-02-02 | 2019-11-21 | Epizyme, Inc. | Cancer treatment modalities |
| WO2019071171A1 (en) * | 2017-10-05 | 2019-04-11 | The Board Of Trustees Of The University Of Illinois | Method of treating sickle cell disease |
| CN110669015A (zh) * | 2018-07-03 | 2020-01-10 | 上海喀露蓝科技有限公司 | 一种fgfr抑制剂的制备方法 |
| EP3880202A2 (en) * | 2018-11-16 | 2021-09-22 | ArQule, Inc. | Pharmaceutical combination for treatment of cancer |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| PL3919491T3 (pl) * | 2019-01-29 | 2025-10-20 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Inhibitor akt |
| US20220184147A1 (en) * | 2019-03-04 | 2022-06-16 | Northwestem University | Bacterial enzymatic conversion of anthracycline chemotherapeutics to reduce toxicity and promote diversity among the intestinal microbiota |
| WO2022053708A1 (en) * | 2020-09-14 | 2022-03-17 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma |
| IL301567A (en) * | 2020-09-30 | 2023-05-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | A compound as an AKT KINASE inhibitor |
| CN112225745B (zh) * | 2020-11-16 | 2021-10-12 | 烟台大学 | 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途 |
| EP4486390A1 (en) * | 2022-03-02 | 2025-01-08 | Terremoto Biosciences, Inc | Covalent modifiers of akt1 and uses thereof |
| WO2025034613A1 (en) * | 2023-08-04 | 2025-02-13 | Terremoto Biosciences, Inc. | 3h-imidazo[4,5-b]pyridine compounds as non-covalent modifiers of akt1 and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010078430A1 (en) * | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds |
| TWI461410B (zh) * | 2008-12-30 | 2014-11-21 | Arqule Inc | 經取代之５，６－二氫－６－苯基苯並〔f〕異喹啉－２－胺化合物類 |
| EP2414358A1 (en) * | 2009-03-31 | 2012-02-08 | ArQule, Inc. | Substituted tetrahydropyrazolo-pyrido-azepin compounds |
| DK2519522T3 (en) * | 2009-12-30 | 2014-12-08 | Arqule Inc | SUBSTITUTED IDAZOPYRIDINYL AMINOPYRIDINE COMPOUNDS |
| KR20190015600A (ko) | 2011-06-24 | 2019-02-13 | 아르퀼 인코포레이티드 | 치환된 이미다조피리디닐-아미노피리딘 화합물 |
| US8815854B2 (en) | 2011-06-24 | 2014-08-26 | Arqule, Inc. | Substituted imidazopyridinyl compounds |
-
2015
- 2015-09-04 EP EP15838638.3A patent/EP3189036B1/en active Active
- 2015-09-04 AU AU2015311751A patent/AU2015311751B2/en not_active Ceased
- 2015-09-04 BR BR112017004459A patent/BR112017004459A2/pt not_active IP Right Cessation
- 2015-09-04 RU RU2019142694A patent/RU2019142694A/ru unknown
- 2015-09-04 WO PCT/US2015/048520 patent/WO2016037044A1/en not_active Ceased
- 2015-09-04 CN CN202010227563.XA patent/CN111494378A/zh active Pending
- 2015-09-04 KR KR1020177008846A patent/KR20170045748A/ko not_active Abandoned
- 2015-09-04 CN CN201580060093.XA patent/CN107074769B/zh not_active Expired - Fee Related
- 2015-09-04 JP JP2017512759A patent/JP6574245B2/ja not_active Expired - Fee Related
- 2015-09-04 CA CA2958770A patent/CA2958770A1/en not_active Abandoned
- 2015-09-04 ES ES15838638T patent/ES2955926T3/es active Active
- 2015-09-04 US US14/845,795 patent/US9949981B2/en active Active
- 2015-09-04 MX MX2017002892A patent/MX382891B/es unknown
- 2015-09-04 RU RU2017111204A patent/RU2711500C2/ru active
- 2015-09-04 SG SG11201701704XA patent/SG11201701704XA/en unknown
-
2017
- 2017-02-22 IL IL250715A patent/IL250715B/en active IP Right Grant
-
2019
- 2019-08-15 JP JP2019149011A patent/JP6837525B2/ja not_active Expired - Fee Related
-
2020
- 2020-06-04 AU AU2020203706A patent/AU2020203706B2/en not_active Expired - Fee Related
- 2020-08-31 IL IL277028A patent/IL277028A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN111494378A (zh) | 2020-08-07 |
| WO2016037044A1 (en) | 2016-03-10 |
| CN107074769A (zh) | 2017-08-18 |
| ES2955926T3 (es) | 2023-12-11 |
| MX2017002892A (es) | 2017-06-06 |
| RU2711500C2 (ru) | 2020-01-17 |
| MX382891B (es) | 2025-03-13 |
| IL250715B (en) | 2020-09-30 |
| EP3189036B1 (en) | 2023-07-19 |
| RU2017111204A (ru) | 2018-10-05 |
| AU2020203706B2 (en) | 2022-01-13 |
| CA2958770A1 (en) | 2016-03-10 |
| RU2019142694A (ru) | 2020-02-26 |
| AU2015311751A1 (en) | 2017-03-09 |
| IL277028A (en) | 2020-10-29 |
| KR20170045748A (ko) | 2017-04-27 |
| JP6837525B2 (ja) | 2021-03-03 |
| US20160067260A1 (en) | 2016-03-10 |
| EP3189036A4 (en) | 2018-04-04 |
| RU2017111204A3 (https=) | 2019-03-25 |
| EP3189036A1 (en) | 2017-07-12 |
| IL250715A0 (en) | 2017-04-30 |
| JP2017526698A (ja) | 2017-09-14 |
| AU2020203706A1 (en) | 2020-06-25 |
| AU2015311751B2 (en) | 2020-03-12 |
| CN107074769B (zh) | 2020-04-07 |
| US9949981B2 (en) | 2018-04-24 |
| SG11201701704XA (en) | 2017-04-27 |
| JP6574245B2 (ja) | 2019-09-11 |
| JP2020002148A (ja) | 2020-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017004459A2 (pt) | composições e métodos para o tratamento de distúrbios de proliferação | |
| MX2017012613A (es) | Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm. | |
| MX387394B (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| MX374346B (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| MX374729B (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4. | |
| PE20090506A1 (es) | DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4 | |
| PH12013501754A1 (en) | Triazolopyridine compounds as pim kinase inhibitors | |
| MX2015013481A (es) | Compuestos heterociclicos fusionados como inhibidores de proteina quinasa. | |
| MX382607B (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa. | |
| DK3805233T3 (da) | (r)- og (s)-enantiomerer af n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazol-carboxamid som irak4-hæmmere til cancerbehandling | |
| BR112012017269A2 (pt) | compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos | |
| BR112016008849B8 (pt) | Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas | |
| BR112017023147A2 (pt) | azabenzimidazóis e seu uso como moduladores do receptor de ampa | |
| BR112015001528A2 (pt) | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| EA201200951A1 (ru) | Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| BR112014009006B8 (pt) | Compostos heterocíclicos e métodos de uso dos mesmos | |
| PH12016502523A1 (en) | Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide | |
| EA202091120A3 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| MX373129B (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| MX2018008362A (es) | Derivados de quinolin-2-ona. | |
| IL284266A (en) | History of (pyridin-2-yl)amine as an inhibitor of TGF-β in cell R1 (ALK5) for cancer treatment | |
| MX2017000522A (es) | Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde. | |
| MX2014011326A (es) | Derivados de 6-(4-(1-amino-3-hidroxiciclobutil) fenil)-5-fenil (furo, tieno o pirrolo) [2, 3-d] pirimidin 4-ona para el tratamiento de cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 213/74 Ipc: A61K 31/444 (2006.01), A61K 31/4545 (2006.01), A61 |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2738 DE 27-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |